According to The Fly, in a report issued on December 7, Matthew Weston from Credit Suisse maintained a Buy rating on AstraZeneca (AZN). The company’s shares closed on Friday at $38.18.
According to TipRanks.com, Weston is ranked #3184 out of 5106 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AstraZeneca with a $54 average price target.
See today’s analyst top recommended stocks >>
AstraZeneca’s market cap is currently $96.82B and has a P/E ratio of 39.58. The company has a Price to Book ratio of 8.11.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.
